- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03692169
The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
The Changes of Retinal and Choroidal Capillaries After Half-dose Photodynamic Therapy Measured by Angio- OCT in Eyes With Central Serous Chorioretinopathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PDT was hypothesized to have a primary effect on the choroidal capillaries, and a number of studies have reported choriocapillary damage and choroidal vascular remodeling after PDT. More recently, although OCTA related CSC research has been conducted, no quantitative report has thoroughly investigated the microstructural changes in the superficial, deep retinal and choroidal capillaries after hd-PDT. The purpose of the present study is to determine the changes in the retinal and choroidal capillaries quantitatively with OCTA after hd-PDT in eyes with CSC.
This is a prospective observational study of patients undergoing hd-PDT for CSC with active leakage in retinal pigment epithelium (RPE) and followed for 3 months. Fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) were performed at baseline; best corrected visual acuity (BCVA), fundus photography, optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up visit after hd-PDT.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Fabao Xu
- Phone Number: 15521250400
- Email: 517311823@qq.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
Guangzhou, Guangdong, China, 510000
- Completed
- Fabao Xu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- CSC diagnosed by FFA and ICGA, where the active leakage was just located in macular fovea with SRF confirmed by OCT
- Patient age ≥18 years
- BCVA ≥35 letters on ETDRS charts
- Persistent CSC for a period of time or patients were anxiety about the symptom and asking for treatment
- Lack of either spontaneous improvement or improvement induced by empirical treatment such as pharmaceutical drug
- The provision of written informed consent -
Exclusion Criteria:
- The presence of any other chorioretinal diseases that may affect the studies, such as age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV)
- Patients who had received any previous treatment, including PDT, intraocular drug injection or focal thermal laser photocoagulation for CSC
- Patients with PED in macular fovea which the average diameter (transverse diameter and vertical diameter) was more than 300 microns
- Patients with high myopia, defined as a refractive error (spherical equivalent) < -6.00 diopters, or an axial length >26.5 mm
- Patients with media opacities, or signal strength index of the images < 60
- Patients under corticosteroid therapy -
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CSC patients
Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns.
This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes.
Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm².
OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
|
Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes.
Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm².
Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of retinal capillaries after hd-PDT
Time Frame: 1 month, 3 month
|
The primary outcome measure is the OCTA-based changes in the retinal capillaries after hd-PDT
|
1 month, 3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of eyes with complete absorption of subretinal fluid(SRF)
Time Frame: 1 month, 3 month
|
The outcome 2 measure is the OCT-based improvement rate (defined as the proportion of eyes with complete absorption of subretinal fluid on OCT images)
|
1 month, 3 month
|
Change of Best Corrected Visual Acuity(BCVA)
Time Frame: 1 month, 3 month
|
The outcome 3 measure is the EDTRS charts-based improvement of Best Corrected Visual Acuity
|
1 month, 3 month
|
Changes of choroidal thickness after hd-PDT
Time Frame: 1 month, 3 month
|
The outcome 4 measure is the OCT-based thinning of choroidal thickness after hd-PDT
|
1 month, 3 month
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSC-PDT-OCTA(ZOC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Serous Chorioretinopathy
-
Shiraz University of Medical SciencesRecruiting
-
Radboud University Medical CenterOogziekenhuis RotterdamRecruitingChronic Central Serous ChorioretinopathyNetherlands
-
Radboud University Medical CenterUniversity of Oxford; University of Cologne; Leiden University Medical Center; University...CompletedChronic Central Serous ChorioretinopathyNetherlands, France, Germany, United Kingdom
-
Università degli Studi di BresciaUnknownChronic Central Serous Chorioretinopathy
-
Manhattan Eye, Ear & Throat HospitalLuEsther T. Mertz Retinal Research CenterCompletedChronic Central Serous ChorioretinopathyUnited States
-
Manhattan Eye, Ear & Throat HospitalCompletedChronic Central Serous ChorioretinopathyUnited States
-
Sun Yat-sen UniversityCompletedAcute Central Serous ChorioretinopathyChina
-
Ankara Universitesi TeknokentCompletedCentral Serous Chorioretinopathy | Chronic Central Serous ChorioretinopathyTurkey
-
Leiden University Medical CenterRadboud University Medical Center; Academisch Medisch Centrum - Universiteit...UnknownChronic Central Serous ChorioretinopathyNetherlands
-
Manhattan Eye, Ear & Throat HospitalAlcon Research; LuEsther T. Mertz Retinal Research CenterCompletedChronic Central Serous ChorioretinopathyUnited States
Clinical Trials on Half-dose photodynamic therapy
-
Surugadai Nihon University HospitalTeikyo UniversityCompletedChronic Central Serous ChorioretinopathyJapan
-
Radboud University Medical CenterUniversity of Oxford; University of Cologne; Leiden University Medical Center; University...CompletedChronic Central Serous ChorioretinopathyNetherlands, France, Germany, United Kingdom
-
Università degli Studi di BresciaUnknownChronic Central Serous Chorioretinopathy
-
Peking University People's HospitalRecruitingCentral Serous Chorioretinopathy | Therapy, PhotodynamicChina
-
University of TorontoCompleted
-
The Third Xiangya Hospital of Central South UniversityCompletedHypertension | Arterial HypertensionChina
-
Tufts Medical CenterBrigham and Women's Hospital; Poznan University of Medical Sciences; Baystate... and other collaboratorsCompletedBronchopulmonary Dysplasia | Respiratory Distress Syndrome in Premature InfantUnited States
-
University of North Carolina, Chapel HillNaturex SACompleted
-
Centre Hospitalier Universitaire de NiceWithdrawnDystrophic Epidermolysis BullosaFrance
-
Lithuanian University of Health SciencesCompleted